For over a decade, See, Test & Treat, a CAP Foundation, pathologist-led program, has extended compassionate preventive care to medically at-risk populations faced with financial, linguistic, social, and cultural barriers to health care. In an April 11, 2022 tweet, CAP Foundation (@CAPFndn) stated, “Our #SeeTestTreat look has been refreshed! The new #SeeTestTreat identity strengthens the program’s support and firm commitment to the Foundation’s initiatives to place pathologists at the forefront of patient care.” We hopped over to the program’s updated webpage and found helpful information about all things See, Test & Treat. From the initial application to an extensive event toolkit to materials to distribute to potential host institutions, the Foundation gives pathologists the tools they need to lead a successful event.
As we reported in January 2021, the challenges brought on by the pandemic had temporarily halted See, Test & Treat events in 2020. There was much buzz and excitement for the program in 2021. And what a year it was! Thanks to pathologist leaders and clinician volunteers, over 660 patients in medically underserved communities received free cervical and breast cancer screening. With a full calendar of See, Test & Treat events in 2022, this year is sure to bring compassionate care to even more communities across the country.
It takes a team of volunteer healthcare professionals to make these events possible. Through the coordination of a pathologist, See, Test & Treat brings together specialists like gynecologists and radiologists to provide free, preventive care to underserved women. While the application period for 2022 events has closed, information regarding the 2023 See, Test & Treat application period will be available in spring 2022.
Let’s keep shining a light on See, Test & Treat! Share your experience as a See, Test & Treat pathologist lead. DM us on Twitter @instapathbio or email Kristin at firstname.lastname@example.org.
To learn more about Luci, visit our Products page or email email@example.com. Instapath was founded in 2017 by the same engineers and scientists who developed the original prototypes. Our vision is to enable patients to immediately know their cancer diagnosis instead of waiting days or weeks for the results. Instapath builds microscopy platforms to improve patient care in the form of faster turnaround times and prevention of high risk and costly repeat biopsy procedures. Further, our goal is to provide users with a seamless, modernized digital pathology workflow with tools to complete all pathology evaluations needed to provide the most precise and efficient diagnoses for patients.